NCT04498286View on ClinicalTrials.gov

COVID-19 and SARS-CoV-2 Antibodies in Multiple Sclerosis Patients

CompletedOBSERVATIONAL
Enrollment

546

Participants

Timeline

Start Date

August 8, 2020

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2021

Conditions
Multiple Sclerosis
Interventions
DIAGNOSTIC_TEST

Testing of SARS-CoV-2 antibodies

Sars-CoV-2 RBD total antibody test developed by Sanquin

Trial Locations (1)

Unknown

VU medical center, Amsterdam

All Listed Sponsors
lead

Zoé van Kempen

OTHER

NCT04498286 - COVID-19 and SARS-CoV-2 Antibodies in Multiple Sclerosis Patients | Biotech Hunter | Biotech Hunter